Acumen doses first patient in Phase II Alzheimer’s disease trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 09, 2024 at 07:22: PM
via Acumen Pharmaceuticals has dosed the first patient in ALTITUDE-AD, a Phase II trial designed to evaluate the clinical efficacy and safety of its lead drug sabirnetug (ACU193) in patients with early Alzheimer’s disease.

article source
 




Similar threads

cafead
AAIC 2023 – Acumen’s new amyloid approach impresses
Replies
0
Views
60
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease
Replies
0
Views
120
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
All in on amyloid, Acumen Pharma’s IPO raises $160M for Alzheimer’s drug R&D
Replies
0
Views
109
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Acumen rides aducanumab, amyloid and Alzheimer's waves on its IPO voyage
Replies
0
Views
91
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Emergent to donate 50,000 vaccine doses to address mpox outbreak in Africa
Replies
0
Views
6
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote